| Name | Title | Contact Details |
|---|
Executive Source International is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Delta Health Technologies is a Altoona, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`re Villa Healthcare, and we make people better. Of course, we`re focused on quality care and good outcomes. But we`re here to do so much more. At Villa, we offer the very best in post-acute and long-term care. Our focus is providing exceptional clinical services by people who truly care, in an environment that promotes healing and wellness. Villa`s leadership has a vision of rising above the status quo—of never settling, and of shattering the old image of this industry. We`ve always wanted to be a part of something greater, and we`ve made that a reality by both making people better and by creating and sharing opportunities. We currently have 22 facilities in four different states*. As Villa has grown, we have redoubled our efforts to ensure that the Villa experience is the same at every location. By extensively renovating our centers and hiring the best people we can, we are making our mark in the world of healthcare. It`s how Villa makes people better.
Douglas County Hospital is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Alexandria, MN. To find more information about Douglas County Hospital, please visit www.dchospital.com
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.